c*e
2 楼
来了七年,只发了两篇七分一作。
回国有人要吗?
回国有人要吗?
f*u
3 楼
到居住地的政府(county)网页上该能查到你房产税的数额,很多地方这都是对公众公开的信
息
息
d*m
5 楼
关键取决于你是博士来的还是博后来的吧。前者你就比好多人强了,后者你基本就垫底
了。
了。
i*1
12 楼
工作量大吗?
M*n
14 楼
回国要抓紧阿.
过两年,国内的postdoc也发7分了,你就没有机会了。
在美国7年postdoc要拿faculty还是比较吃力的。
过两年,国内的postdoc也发7分了,你就没有机会了。
在美国7年postdoc要拿faculty还是比较吃力的。
b*M
24 楼
是不是 loser,在于自己的感受。从文章看,一般水平,还能混得下去。若干年后的问
题值得考虑。
题值得考虑。
k*o
26 楼
有CNS也算卢瑟了,呵呵,大家一起卢瑟
d*m
27 楼
这要不就是得瑟;要不就是发了CNS也不知道自己在干什么的那种。
l*1
29 楼
Please refer below company CEO his resume:
//www.epitomics.com/about/about_management/
Epitomics dot Com CEO Guoliang Yu, Ph.D.
Dr. Guo-Liang is currently the Chairman and President of Epitomics, Inc. an
emerging biotech company dedicated to the development of innovative next-
generation monoclonal antibodies. Before starting Epitomics, he was the
Senior Vice-President of Research and Development in Mendel Biotechnology
Inc. Dr. Yu has broad technological and scientific experiences in many
aspects of biotechnology. His interests cover genomics, molecular biology,
genetics, immunology, cancer biology, and plant physiology and drug
discovery. He is co-inventor and co-author of over 100 patents and
scientific articles. Dr. Yu received Ph.D. degree in Molecular Biology from
the University of California, Berkeley and B.S. degree in Biochemistry from
Fudan University, China. Guo-Liang conducted his Post-doctoral training in
Dr. Frederick Ausubel’s laboratory at the Harvard Medical School. Dr. Yu
founded Chinese Biopharmaceutical Association (CBA) headquartered in
Washington DC and is an Executive Member of several professional
organizations in U.S and China.
from
//tbiweb.org/tbi/editors.php
PhD studying
had
more papers from Molecular Biology from the University of California,
Berkeley
Cell (1991) 1st author:
//www.ncbi.nlm.nih.gov/pubmed/1934071
Cell (1990) 1st author
//www.ncbi.nlm.nih.gov/pubmed/1689810
-------
PD training only two papers from Harvard Medical School
unknown one journal 1st author
//www.ncbi.nlm.nih.gov/pubmed/8400373
Cell (1994) 3rd author
//www.ncbi.nlm.nih.gov/pubmed/7923358
citation:
//www.ncbi.nlm.nih.gov/pmc/articles/PMC144313/
-----
this kind of performance never can become tenure tracking faculty PI/AP in
US,
so DIHimself VB business in US and China from then...
plus
临床诊断试剂开发研究员(2名)
生物学,医学专业博士学历 xxx 从事临床诊断试剂
开发工作,领导并参与靶标设定,抗体开发、和产品质量评估相关的研发工作,具有扎
实的免疫学,生物化学,蛋白质操作知识及临床诊断试剂开发领域的知识及相关经验;
具有相关项目管理经验者优先;善于沟通,具有优秀的协作及协调能力;具有严谨的科
学训练及独立开展工作的能力,有成功开发项目经验者优先 YYY
//job.zjtcm.net/news/48201227153030.html
【在 c******e 的大作中提到】
: 来了七年,只发了两篇七分一作。
: 回国有人要吗?
//www.epitomics.com/about/about_management/
Epitomics dot Com CEO Guoliang Yu, Ph.D.
Dr. Guo-Liang is currently the Chairman and President of Epitomics, Inc. an
emerging biotech company dedicated to the development of innovative next-
generation monoclonal antibodies. Before starting Epitomics, he was the
Senior Vice-President of Research and Development in Mendel Biotechnology
Inc. Dr. Yu has broad technological and scientific experiences in many
aspects of biotechnology. His interests cover genomics, molecular biology,
genetics, immunology, cancer biology, and plant physiology and drug
discovery. He is co-inventor and co-author of over 100 patents and
scientific articles. Dr. Yu received Ph.D. degree in Molecular Biology from
the University of California, Berkeley and B.S. degree in Biochemistry from
Fudan University, China. Guo-Liang conducted his Post-doctoral training in
Dr. Frederick Ausubel’s laboratory at the Harvard Medical School. Dr. Yu
founded Chinese Biopharmaceutical Association (CBA) headquartered in
Washington DC and is an Executive Member of several professional
organizations in U.S and China.
from
//tbiweb.org/tbi/editors.php
PhD studying
had
more papers from Molecular Biology from the University of California,
Berkeley
Cell (1991) 1st author:
//www.ncbi.nlm.nih.gov/pubmed/1934071
Cell (1990) 1st author
//www.ncbi.nlm.nih.gov/pubmed/1689810
-------
PD training only two papers from Harvard Medical School
unknown one journal 1st author
//www.ncbi.nlm.nih.gov/pubmed/8400373
Cell (1994) 3rd author
//www.ncbi.nlm.nih.gov/pubmed/7923358
citation:
//www.ncbi.nlm.nih.gov/pmc/articles/PMC144313/
-----
this kind of performance never can become tenure tracking faculty PI/AP in
US,
so DIHimself VB business in US and China from then...
plus
临床诊断试剂开发研究员(2名)
生物学,医学专业博士学历 xxx 从事临床诊断试剂
开发工作,领导并参与靶标设定,抗体开发、和产品质量评估相关的研发工作,具有扎
实的免疫学,生物化学,蛋白质操作知识及临床诊断试剂开发领域的知识及相关经验;
具有相关项目管理经验者优先;善于沟通,具有优秀的协作及协调能力;具有严谨的科
学训练及独立开展工作的能力,有成功开发项目经验者优先 YYY
//job.zjtcm.net/news/48201227153030.html
【在 c******e 的大作中提到】
: 来了七年,只发了两篇七分一作。
: 回国有人要吗?
b*y
33 楼
如果过来读书,很厉害
如果过来直接薄厚,中等吧,也没多卢瑟
大家都差不多
如果过来直接薄厚,中等吧,也没多卢瑟
大家都差不多
相关阅读
如何通过结构来预测两个蛋白相互结合的可能性看了这个觉得靠谱:庄没到到诺奖的真正原因(转帖)失物招领(和本版主题无关,请版主手下留情)转录因子的结合motif在某基因的3'国家自然科学基金能给自己发工资吗stem cell疾病治疗前景大家怎么看?Analyze estrogen/estradiol treated samples using RNAseqpaper helps!杂志同时刊登同一方向两篇文章,他们是同一天提交的!有谁做PTEN相关的课题吗?PY P-AGC 和P-AKT啥意思名校大牛薄厚 vs 小公司小offer 真心求教谁能帮帮忙, 找一篇文献有人了解UNC Xian Chen实验室?求助:同样的实验结果不同方法怎么分开发表文章Bioinformatics Position Opened in California总结下细胞老化的最佳故事Look for protein complexes说个诺奖小故事(你们对庄的猜疑太过了)求 paper有人用过Invitrogen的iBind吗?